Nemolizumab Demonstrates Sustained Long-Term Benefit in Prurigo Nodularis: Study

Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and good tolerability for up to 3 years in patients with moderate-to-severe prurigo nodularis. By selectively inhibiting the IL-31 receptor alpha, nemolizumab targets a central neuroimmune pathway responsible for chronic itch and lesion persistence.

At 148 weeks, approximately 70% of patients achieved clear or almost clear skin, while more than 85% experienced over 75% lesion healing, indicating sustained disease control. These findings support nemolizumab as an effective long-term therapeutic option for prurigo nodularis with a favorable safety profile.

Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years. Results will be presented at 2026 Winter Clinical Miami and build on previous data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one with a LTE study.

“Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, long-term disease control is critical for patients. These data show that Nemluvio can make a meaningful difference to people’s lives by improving itch, skin lesions and quality of life up to three years, with a well-tolerated safety profile.”

Doctor shawn kwatra, m.d., Lead investigator of olympia program, Joseph w. Burnett endowed professor and chairman of dermatology university of maryland school of medicine

Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life

The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and included 508 patients from the phase II trial and the OLYMPIA 1 and 2 phase III trials. At Week 148, in evaluable patients, the interim analysis showed that Nemluvio maintained long-term disease control with a consistent safety profile:

• Over 70% of patients achieved clear or almost clear skin lesions based on Investigator’s Global Assessment score, and over 85% achieved more than 75% of healed lesions based on prurigo activity score.

• Over 85% of patients achieved a clinically meaningful itch improvement, and about three-quarters attained an itch-free or nearly itch-free state.

• About 90% of patients achieved a clinically meaningful improvement in quality of life, and >50% achieved a Dermatology Life Quality Index score of zero or one, meaning no effect of the disease on quality of life.

• The long-term safety profile of Nemluvio remained consistent with previous findings and aligned with previously established safety data for prurigo nodularis.

“We recognize that prurigo nodularis is a chronic, debilitating condition that patients often struggle with for many years. Our goal has always been to generate robust, long-term evidence on how to ease such disease burden for patients suffering from prurigo nodularis, drawing on data from the largest completed pivotal clinical program and now the longest extension study reported in this disease to date.”

Baldo scassellati sforzolini, m.d., ph.d., Global head of r&d, Galderma

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2-5 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis. Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the U.S. and EU.

About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.

Nemluvio was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, and patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the EU, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing.

About prurigo nodularis

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas. It is estimated to affect between 7-111 people per 100,000 in the EU depending on the country and up to 181,000 people in the U.S. The majority of patients report that the persistent itch negatively impacts their quality of life. Furthermore, the intense itch associated with prurigo nodularis results in significant sleep disturbance and further contributes to reduced quality of life.